{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atazanavir+Sulphate&page=3", "query": { "intervention": "Atazanavir Sulphate", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 141, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atazanavir+Sulphate&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atazanavir+Sulphate&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T21:12:27.837Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02269917", "title": "Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "D/C/F/TAF", "type": "DRUG" }, { "name": "Boosted Protease Inhibitor (bPI)", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1149, "start_date": "2015-03", "completion_date": "2020-10", "has_results": true, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269917" }, { "nct_id": "NCT01602822", "title": "Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kenneth H. Mayer, MD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2012-02", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01602822" }, { "nct_id": "NCT00384904", "title": "Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir/Ritonavir", "type": "DRUG" }, { "name": "Atazanavir/Ritonavir + Famotidine", "type": "DRUG" }, { "name": "Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2006-12", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2010-02-05", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 3, "location_summary": "Voorhees Township, New Jersey • Chapel Hill, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00384904" }, { "nct_id": "NCT00242216", "title": "\"The Once A Day Protease Inhibitor Regimens\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ritonavir-boosted atazanavir", "type": "DRUG" }, { "name": "ritonavir-boosted fosamprenavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2004-05", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-01-15", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00242216" }, { "nct_id": "NCT02386098", "title": "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "BMS-955176", "type": "DRUG" }, { "name": "Atazanavir (ATV)", "type": "DRUG" }, { "name": "Ritonavir (RTV)", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Tenofovir (TDF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2015-07-08", "completion_date": "2017-06-07", "has_results": true, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 16, "location_summary": "Beverly Hills, California • Los Angeles, California • Palm Springs, California + 13 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02386098" }, { "nct_id": "NCT00135434", "title": "Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir/Ritonavir/Lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2004-09", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2011-04-08", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 1, "location_summary": "Hamilton, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135434" }, { "nct_id": "NCT00624195", "title": "Clinical Trial of CNS-targeted HAART (CIT2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "FDA Approved Antiretroviral Therapy (see list below)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2007-03", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-04-23", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 5, "location_summary": "San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624195" }, { "nct_id": "NCT00756730", "title": "Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ATV/r", "type": "DRUG" }, { "name": "DRV/r", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2008-09", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2017-08-21", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00756730" }, { "nct_id": "NCT02605954", "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "Third Antiretroviral Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2015-11-18", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605954" }, { "nct_id": "NCT03631732", "title": "Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" }, { "name": "Third Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 496, "start_date": "2018-08-28", "completion_date": "2020-08-19", "has_results": true, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-10-05T21:12:27.837Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631732" } ] }